Connect Sign In
Researchers at ARUP Laboratories made significant contributions to the advancement of laboratory medicine in 2021 as coauthors of more than 150 peer-reviewed articles.
Two years into the COVID-19 pandemic, when the highly contagious Omicron variant of SARS-CoV-2 has infected millions in the United States alone, most of us have some immunity against the virus.
ARUP Transfusion Medicine has partnered with machine-learning experts at the U of U to develop and validate a method that can predict the need for transfusion during cardiothoracic surgery.
PacBio and ARUP Laboratories announced they are collaborating on a study intended to evaluate whether the solve rate for rare disease cases can be increased.
Deep Bio, a leading company in artificial intelligence (AI) cancer diagnostics, announced it obtained an approval from the University of IRB for a real-world implementation study.
About 200 research park and innovation district leaders from around the globe visited ARUP to hear how Research Park’s largest tenant has become a model for startups born in research institutions.
ARUP Laboratories’ intentional design of environmentally friendly features in its new state-of-the-art laboratory facility has already paid off in the form of a large rebate
Utah Rep. Burgess Owens visited ARUP Laboratories as part of a BioUtah BioHive tour of homegrown companies that have put Utah on the map as the center of innovation in the life sciences industry.
ARUP announced an investment in Techcyte Inc. as part of the company’s new $21 million funding round. This will enable Techcyte to expand the development team for its digital diagnostics platform.
A new antibody test that has earned EUA from the FDA effectively detects SARS-CoV-2 neutralizing antibodies, according to an analysis recently published by experts at ARUP Laboratories.
Deep Bio announced a research collaboration agreement with ARUP Laboratories. Deep Bio’s AI-based prostate cancer diagnosis software will be used for the joint research.
GenomOncology announced that ARUP has chosen to extend its use of the GenomOncology (GO) Precision Oncology API Suite by integrating the GO Clinical Trial and Therapy Matching APIs into its workflows.
